Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 3, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Plasmablastic lymphoma: a systematic review.

Jorge J Castillo1, John L Reagan

  • 1The Warren Alpert Medical School of Brown University, Division of Hematology and Oncology, The Miriam Hospital, Providence, RI, USA. jcastillo@lifespan.org

Thescientificworldjournal
|March 29, 2011
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world outcomes of plasmablastic lymphoma: Treatment approaches and survival outcomes in the PLASMABLAT-001 cohort.

Leukemia research·2026
Same author

A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.

Haematologica·2026
Same author

Plasmablastic Lymphoma: 2026 Update on Diagnosis, Risk Stratification, and Management.

American journal of hematology·2026
Same author

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

The Lancet. Haematology·2026
Same author

Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells.

Blood advances·2026
Same author

Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.

Blood cancer journal·2026
Same journal

Agronomic Performance and Nutritive Value Evaluation of Desho Grass Varieties Under Supplementary Irrigation in Western Oromia, Ethiopia.

TheScientificWorldJournal·2026
Same journal

Physicians' and Hospital Administrators' Perspectives of Diagnosis-Related Groups (DRGs) in High-Income Countries: A Systematic Review.

TheScientificWorldJournal·2026
Same journal

The Eco-Friendly Preparation of Se, Zn, and Ag MONPs and Their Current Medical Applications and Drug Delivery for AD Diseases.

TheScientificWorldJournal·2026
Same journal

Fear of COVID-19: A Comparative Study Among University Students in Peru.

TheScientificWorldJournal·2026
Same journal

Opportunities and Challenges of Integrating Ethiopian Traditional Medicine System Into Modern Medicine: A Narrative Review.

TheScientificWorldJournal·2026
Same journal

Exploring the Antiparasitic Activity of the Sea Cucumber Isostichopus sp. aff. badionotus From the Northern Coast of Colombia Against Trypanosoma cruzi.

TheScientificWorldJournal·2026
See all related articles

Plasmablastic lymphoma (PBL), an aggressive cancer, presents diagnostic and therapeutic challenges. Recent research reviews advances in understanding PBL, including its characteristics, Epstein-Barr virus association, and the need for intensive therapies.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Plasmablastic lymphoma (PBL) is an aggressive diffuse large B-cell lymphoma variant.
  • It primarily affects the oral cavity of HIV-infected individuals but also occurs in HIV-negative settings.
  • PBL poses diagnostic and therapeutic challenges due to its morphology, lack of CD20 expression, high relapse rates, and poor prognosis.

Purpose of the Study:

  • To systematically review recent advances in the epidemiology, pathophysiology, and clinical, pathologic, and molecular characteristics of PBL.
  • To discuss current therapeutic strategies and prognosis for patients with PBL.
  • To highlight new diagnostic markers, the association with Epstein-Barr virus, and the need for more intensive therapies.

Main Methods:

  • Systematic review of recent literature on Plasmablastic Lymphoma.

Related Experiment Videos

Last Updated: Jun 3, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

  • Analysis of case reports and case series to consolidate data.
  • Focus on epidemiological, pathophysiological, clinical, pathological, molecular, and therapeutic aspects.

    • Main Results:

    • Understanding of PBL has increased in both HIV-positive and -negative individuals.
    • New pathological markers are emerging for improved diagnosis.
    • The association with Epstein-Barr virus and the need for more intensive therapies are key considerations.

    Conclusions:

    • Plasmablastic lymphoma remains a challenging malignancy requiring further research.
    • Advances in understanding its characteristics and associations are crucial for improving patient outcomes.
    • More intensive therapeutic approaches may be necessary to combat high relapse rates.